Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MATCH-1: Topical HDIT101 for Recurrent Orolabial Herpes
NCT04539483Phase 2Terminated
- Sponsor
- Heidelberg ImmunoTherapeutics
- Start
- Oct 2020
- Primary completion
- May 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in herpes labialis comparing HDIT101 with Placebo (2 arms). Primary endpoint: Number of recurrences after topical HDIT101 versus placebo after 12 months. Started Oct 2020; status: terminated.
02
Drugs
HDIT101
03
Conditions
herpes labialis
Beyond the preview
Go deeper on NCT04539483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04539483.